North America Multiple Myeloma Therapeutics Market by Treatment Type (Chemotherapy (Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal doxorubicin (Doxil)) and Alkylating agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)), Targeted Therapy( Proteasome Inhibitor(Bortezomib (Velcade), Carfilzomib (Kyprolis)), by Drug Type (Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)), Immunomodulatory Agents(Thalidomide (Thalomid), Lenalidomide (Revlimid), Arsenic trioxide (Trisenox), Plerixafor (Mozobil)) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

North America Multiple Myeloma Therapeutics Market by Treatment Type (Chemotherapy (Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal doxorubicin (Doxil)) and Alkylating agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)), Targeted Therapy( Proteasome Inhibitor(Bortezomib (Velcade), Carfilzomib (Kyprolis)), by Drug Type (Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)), Immunomodulatory Agents(Thalidomide (Thalomid), Lenalidomide (Revlimid), Arsenic trioxide (Trisenox), Plerixafor (Mozobil)) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

ID: 859 | Pages: 144 | November 2016 | Region: North America


The North America Multiple Myeloma Therapeutics Market was worth $2.45 billion in 2016 and estimated to be growing at a CAGR of 4.37%, to reach $3.03 billion by 2021. North America dominated the market with highest revenue because of stability of key manufacturers in the region.

Several leading drugs are emerging in the market, mostly were approved over the past few years, and have enhanced median surviving rates by about 50%. The advancement of drug therapy and stem-cell relocation for the treatment of myeloma and the development of new agents has contributed in increasing the survival time for patients suffering from Myeloma.

Augmented demand of therapeutic products for the management of blood diseases is a key driver of the multiple myeloma therapeutic market. This market growth is also driven by increasing incidence of the disease cases, sustained success of revlimid and developing additional treatments. Though, inflexible regulations by several governments impede the growth of North America multiple myeloma therapeutic market.

The North America Multiple Myeloma Therapeutics Market is segmented on the basis of Treatment Type into Chemotherapy which is further segmented into Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal doxorubicin (Doxil)) and Alkylating agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)) and Targeted Therapy ( Proteasome Inhibitor (Bortezomib (Velcade), Carfilzomib (Kyprolis)), by Drug Type into Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)) and Immunomodulatory Agents (Thalidomide (Thalomid), Lenalidomide  (Revlimid), Arsenic trioxide  (Trisenox), Plerixafor  (Mozobil)). With the advancement in technology targeted therapy is on a high growth due to its advantages over chemotherapy such as lesser side effects.

Based on geography the market is analysed under various regions namely, USA and Canada. USA is leading market for multiple myeloma therapeutics all over the globe and Canada is anticipated to grow at a high rate in the forecast period.

Some of the key contributors in the industry include AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc. ,Teva Pharmaceutical Industries Ltd. ,TG Therapeutics Inc. and Johnson and Johnson.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments               

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 By Treatment Type                 

                                5.1.1 Chemotherapy      

                                                5.1.1.1 Anthracycline antibiotic

                                                5.1.1.2 Alkylating agent

                                5.1.2 Targeted Therapy

                                                5.1.2.1 Proteasome inhibitor                                                      

                5.2 By Drug Type                             

                                5.2.1 Corticosteroids      

                                                5.2.1.1 Dexamethasone (Decadron)

                                                5.2.1.2 Prednisone (Deltasone/Orasone)

                                5.2.2 Immunomodulatory agents             

                                                5.2.2.1 Thalidomide (Thalomid)

                                                5.2.2.2 Lenalidomide  (Revlimid)

                                                5.2.2.3 Arsenic trioxide  (Trisenox)

                                                5.2.2.4 Plerixafor  (Mozobil)

6. Geographical Analysis                                              

                6.1 Introduction                               

                6.2 United States                            

                6.3 Canada                         

7. Pipeline Product Analysis                                        

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                    

                7.3 Molecular Targets in the Pipeline                                      

                7.4 Clinical Trials (by Stage of Development, Indication, Molecule Type and Molecular Target)

                                7.4.1 Failure Rate

                                7.4.2 Clinical Trial Duration           

                                7.4.3 Clinical Trial             

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental       

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services              

                                8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                        

                9.1 AB Science SA                            

                                9.1.1 Overview 

                                9.1.2 Product Analysis   

                                9.1.3 Strategic Evaluation and Operations            

                                9.1.4 Financial analysis  

                                9.1.5 Legal issues             

                                9.1.6 Recent Developments       

                                9.1.7 SWOT analysis       

                                9.1.8 Analyst View          

                9.2 AbbVie Inc.                 

                9.3 Ablynx NV                   

                9.4 Acceleron Pharma Inc.                           

                9.5 IGF Oncology LLC.                    

                9.6 ImmunGene Inc.                      

                9.7 Millennium Pharmaceuticals Inc.                       

                9.8 MimiVax LLC                              

                9.9 Mirna Therapeutics                 

                9.10 RedHill Biopharma Ltd.                        

                9.11 Rhizen Pharmaceuticals S.A.                             

                9.12 Terpenoid Therapeutics Inc.                             

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                      

                10.4 New Product Launches                       

11. Expert Opinions                                        

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. North America Multiple Myeloma Therapeutics Market By Region, From 2016-2021 (USD Billion)
  2. North America Multiple Myeloma Therapeutics Market By Treatment Type, From 2016-2021 (USD Billion)
  3. North America Chemotherapy Market By Region, From 2016-2021 (USD Billion)
  4. North America Targeted Therapy Market By Region, From 2016-2021 (USD Billion)
  5. North America Multiple Myeloma Therapeutics Market By Drug Type, From 2016-2021 (USD Billion)
  6. North America Corticosteroids Market By Region, From 2016-2021 (USD Billion)
  7. North America Immunomodulatory agents Market By Region, From 2016-2021 (USD Billion)
  8. United States Multiple Myeloma Therapeutics Market By Treatment Type, From 2016-2021 (USD Billion)
  9. United States Multiple Myeloma Therapeutics Market By Drug Type, From 2016-2021 (USD Billion)
  10. Canada Multiple Myeloma Therapeutics Market By Treatment Type, From 2016-2021 (USD Billion)
  11. Canada Multiple Myeloma Therapeutics Market By Drug Type, From 2016-2021 (USD Billion)
  12. North America Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  13. North America Anthracycline Antibiotic Market By Region, From 2016-2021 (USD Billion)
  14. North America Alkylating Agent Market By Region, From 2016-2021 (USD Billion)
  15. United States Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  16. Canada Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  17. North America Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  18. North America Melphalan (Alkeran) Market By Region, From 2016-2021 (USD Billion)
  19. North America Liposomal doxorubicin (Doxil) Market By Region, From 2016-2021 (USD Billion)
  20. United States Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  21. Canada Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  22. North America Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  23. North America Doxorubicin (Adriamycin) Market By Region, From 2016-2021 (USD Billion)
  24. North America Cyclophosphamide (Neosar) Market By Region, From 2016-2021 (USD Billion)
  25. North America Vincristine (Oncovin) Market By Region, From 2016-2021 (USD Billion)
  26. North America Carmustine (BiCNU) Market By Region, From 2016-2021 (USD Billion)
  27. United States Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  28. Canada Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  29. North America Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2016-2021 (USD Billion)
  30. North America Bortezomib (Velcade) Market By Region, From 2016-2021 (USD Billion)
  31. North America Carfilzomib (Kyprolis) Market By Region, From 2016-2021 (USD Billion)
  32. United States Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2016-2021 (USD Billion)
  33. Canada Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2016-2021 (USD Billion)
  34. North America Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2016-2021 (USD Billion)
  35. North America Dexamethasone (Decadron) Market By Region, From 2016-2021 (USD Billion)
  36. North America Prednisone (Deltasone/Orasone) Market By Region, From 2016-2021 (USD Billion)
  37. United States Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2016-2021 (USD Billion)
  38. Canada Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2016-2021 (USD Billion)
  39. North America Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2016-2021 (USD Billion)
  40. North America Thalidomide (Thalomid) Market By Region, From 2016-2021 (USD Billion)
  41. North America Lenalidomide (Revlimid) Market By Region, From 2016-2021 (USD Billion)
  42. North America Arsenic trioxide (Trisenox) Market By Region, From 2016-2021 (USD Billion)
  43. North America Plerixafor (Mozobil) Market By Region, From 2016-2021 (USD Billion)
  44. United States Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2016-2021 (USD Billion)
  45. Canada Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2016-2021 (USD Billion)
Middle East And Africa Acne Medication Market By Type ( OTC And Prescription Drugs) , By Route Of Administration ( Oral And Topical) , By Drug Class ( Antibiotics, Anti-inflammatory Drugs, Anti Microbial, Combinatio...
Latin America Acne Medication Market By Type ( OTC And Prescription Drugs) , By Route Of Administration ( Oral And Topical) , By Drug Class ( Antibiotics, Anti-inflammatory Drugs, Anti Microbial, Combination Drugs, ...
Asia Pacific Acne Medication Market By Type ( OTC And Prescription Drugs) , By Route Of Administration ( Oral And Topical) , By Drug Class ( Antibiotics, Anti-inflammatory Drugs, Anti Microbial, Combination Drugs, H...
Europe Acne Medication Market By Type ( OTC And Prescription Drugs) , By Route Of Administration ( Oral And Topical) , By Drug Class ( Antibiotics, Anti-inflammatory Drugs, Anti Microbial, Combination Drugs, Hormona...
North America Acne Medication Market By Type ( OTC And Prescription Drugs) , By Route Of Administration ( Oral And Topical) , By Drug Class ( Antibiotics, Anti-inflammatory Drugs, Anti Microbial, Combination Drugs, ...
Acne Medication Market By Type ( OTC And Prescription Drugs) , By Route Of Administration ( Oral And Topical) , By Drug Class ( Antibiotics, Anti-inflammatory Drugs, Anti Microbial, Combination Drugs, Hormonal Agent...
Middle East And Africa Solid Tumor Market By Disease ( Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer And Others) , By Drugs ( Carboplatin, Cisplatin, Gemcitabine, Palcitaxel, Doxoru...
Latin America Solid Tumor Market By Disease ( Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer And Others) , By Drugs ( Carboplatin, Cisplatin, Gemcitabine, Palcitaxel, Doxorubicin, Be...
Asia Pacific Solid Tumor Market By Disease ( Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer And Others) , By Drugs ( Carboplatin, Cisplatin, Gemcitabine, Palcitaxel, Doxorubicin, Bev...
Europe Solid Tumor Market By Disease ( Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer And Others) , By Drugs ( Carboplatin, Cisplatin, Gemcitabine, Palcitaxel, Doxorubicin, Bevacizum...
North America Solid Tumor Market By Disease ( Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer And Others) , By Drugs ( Carboplatin, Cisplatin, Gemcitabine, Palcitaxel, Doxorubicin, Be...
Solid Tumor Market By Disease ( Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer And Others) , By Drugs ( Carboplatin, Cisplatin, Gemcitabine, Palcitaxel, Doxorubicin, Bevacizumab, Erl...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.